Test4TRK Program:
NTRK Testing for Patients with MSI-H mCRC or RAIR DTC

What is an NTRK gene fusion?
A genomic cancer test can identify a Neurotropic Tropomyosin-Receptor Kinase (NTRK) gene fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. NTRK gene fusions are the cause of TRK fusion cancer, which is a term used to describe a variety of common and rare cancers that are caused by this type of fusion.[1-3] Research has identified NTRK gene fusions in more than two dozen types of common and rare solid tumors.[1-4]

Why should I test for NTRK gene fusion?
NTRK gene fusions are a class of oncogenes that have been associated with more aggressive cancer in a range of tumor types. Testing for NTRK gene fusions may help you better understand the primary driver of your patients' cancer and is essential to identify patients who are now eligible for targeted tyrosine kinase receptor (TRK) inhibitor therapy.

What is the Test4TRK testing program?
Test4TRK is a Bayer sponsored program offering laboratory testing for NTRK gene fusions (histology and molecular) to eligible colorectal and thyroid cancer patients at no cost. The test results provide actionable information that may identify appropriate options for your patient. Bayer will cover the full cost of the test regardless of the test results and treatment decision.

What test will be done and what does it test for?
All eligible patients who enroll and opt-in to Test4TRK will receive an RNA- based next-generation sequencing (NGS) based, NTRK NGS Fusion Profile, from NeoGenomics. Patients with an adequate tumor tissue sample will also receive a NeoGenomics Pan-Tropomyosin receptor kinase (TRK) Immunohistochemistry (IHC) test.

Who is eligible for the Test4TRK program?
Any patient with radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC) or metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) with adequate tumor tissue is eligible to enroll in the Test4TRK program to receive genomic cancer testing at no cost. Patients who have not previously undergone a biopsy may still enroll in the program but are responsible for working with their physician to extract a viable tumor specimen and cover any associated expenses.

What type of insurance coverage do my patients need to participate?
Any patient with MSI-H mCRC or RAIR DTC is eligible for Test4TRK regardless of insurance coverage.

Will there be any cost to my patient?
There will be NO COST for patients, healthcare providers or insurance companies for the NGS based or IHC test.

NEO GENOMICS

866.776.5907
neogenomics.com

Test4TRK Program:
NTRK Testing for Patients with MSI-H mCRC or RAIR DTC

What if I get a bill?
No bill will be sent to patients, health care providers or beneficiaries who participate through this program. If a bill is received in error, please discard or contact **866.776.5907, option 3.**

What are the specimen requirements?
NeoGenomics offers NTK gene fusion testing on formalin-fixed paraffin-embedded (FFPE) tissue. The paraffin block is preferred.

Alternatively, for NGS, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives. For IHC, send one (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns) for each test/antibody ordered.

When can I expect results?
Results will be sent to the ordering physician's office or laboratory within 10-14 days after sample is received.

We submitted the test and received the results, now what?
Following a report on the test results, talk to your patient about a potential treatment plan based on the genomic alterations identified. More than 50 cancer therapies are approved by the FDA that are associated with genomic alterations.[5]

Where can I find more information or order more Test Requisition?
Contact your NeoGenomics Territory Business Manager or NeoGenomics Client Services at **866.776.5907, option 3** for more information. Additional forms can be downloaded at **www.neogenomics.com/ntrk-sponsored-testing-program**

What if I am a new client to NeoGenomics?
We are looking forward to working with you! Please contact NeoGenomics Client Services at **866.776.5907, option 3** to set-up your new account.

References

1. Amatu A, SartoreBianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO* Open 2016;1:e000023. doi:10.1136/esmoopen-2015- 000023
2. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. *Genome Med.* 2015;7:129. doi:10.1186/s13073-015-0252-1.
3. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. *Cancer Discov.* 2015;5(1):25-34.
4. Lange AM, Lo H-W. Inhibiting TRK proteins in clinical cancer therapy. *Cancers.* 2018;10(4):E105. doi:10.3390 cancers10040105.
5. National Foundation for Cancer Research. Cancer Genomics. 2017. Accessed December 2019. https://www.nfcr.org/genomics/.

12701 Commonwealth Dr., Suite 9
Fort Myers, FL 33913
Phone: 866.776.5907/ **Fax:** 239.690.4237
neogenomics.com